Sebela Women’s Health Announces Publication of Phase 3 Pivotal Study Results for the Investigational Copper 175 mm² Intrauterine Device (IUD) in Contraception

ROSWELL, Ga., Jan. 24, 2025 /PRNewswire/ — Sebela Women’s Health Inc., a part of Sebela Pharmaceuticals, today announced Contraception published positive results online from the Phase 3 study of the investigational Copper 175mm2 intrauterine device (IUD), concluding that data from this…